title: Transient severe hypotension with once-weekly subcutaneous injection of teriparatide in osteoporotic patient: a case report and insight for the drug interaction between hypotensive agents and teriparatide.
abstract: Teriparatide, a recombinant form of parathyroid hormone, were well recognized as a useful option for the treatment of the osteoporosis. Although some side effects of teriparatide include headache, nausea, dizziness, and limb pain were reported. Here we present a 80-year-old woman of transient asymptomatic hypotension with once-weekly subcutaneous injection of teriparatide for the treatment of osteoporosis with hypertension disease as acute-phase reactions. Systolic blood pressure decreased in both 30 min and 60 min after injection compared with before injection. Heart rate increased with passage of time. Statistically significant were observed among before, 30 min, 60 min after injection of teriparatide. Slight nausea was seen as subjective symptoms with the first and second injection after 30 min. This case indicates careful attention, at least 1 hr, was recommended with weekly subcutaneous injections of teriparatide in the treatment for osoteoproteic patient with hypertension decreases. This is a first report, to the best of our knowledge, to demonstrate the transient asymptomatic hypotension after once-weekly injection of teriparatide with hypertension disease. Transient hypotension occurred after injection of teriparatide during the treatment period and was asymptomatic except for the first 2 injections.
authors: Departments of Rehabilitation Medicine, The Tokushima University Hospital.
authors: Tetsuya
authors: T
authors: Enishi
authors: Hirokazu
authors: H
authors: Uemura
authors: Shinsuke
authors: S
authors: Katoh
authors: Masanori
authors: M
authors: Inatsugi
authors: Sho
authors: S
authors: Minato
authors: Kei
authors: K
authors: Inatsugi
authors: Mikiko
authors: M
authors: Inatsugi
authors: Nori
authors: N
authors: Sato
authors: Koichi
authors: K
authors: Siryo
mesh_terms: D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007022:Hypotension / Q000139:chemically induced*; D007279:Injections, Subcutaneous; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D050071:Bone Density Conservation Agents; D019379:Teriparatide